Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485719 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
A Phase 1 study of Cancer, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 4
- Study locations
NCT00485719: Completed Phase 1 study of Cancer, sponsored by Sanofi.
NCT00485719 is a Phase 1 study of Cancer that has completed, run by Sanofi. The registered enrollment target is 83 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485719, a Phase 1 study of Cancer, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells.
Conditions Studied
Interventions
- DRUG XL765 (SAR245409)
Study Locations (4)
Michigan
- Investigational Site Number 1302 - Detroit
Nebraska
- Investigational Site Number 1435 - Omaha
Texas
- Investigational Site Number 1402 - San Antonio
Other
- Investigational Site Number 3411 - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
What the finished NCT00485719 record still lists
NCT00485719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which XL765 (SAR245409) is the first listed.
NCT00485719 reports a single indexed study location in Michigan, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT00485719 about?
NCT00485719 is a clinical study titled "Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors". The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas i...
What is the current status of trial NCT00485719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2007-06. Estimated completion is 2012-09.
What conditions does trial NCT00485719 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00485719?
The interventions under investigation include: XL765 (SAR245409) (DRUG).
Who is sponsoring clinical trial NCT00485719?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00485719 being conducted?
This trial has 4 study locations across Michigan, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00485719's enrollment target sits among peer trials
83 347th of 615 higher than 268 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia